CEO, MitoRx Therapeutics. Pioneering therapeutics in mitochondrial-driven disease.
UK, Europe
Joined June 2012
- Tweets1.7K
- Following1.3K
- Followers1.2K
- Likes1.5K
Jon Rees PhD retweeted
#NEWS: Today we announced the enrollment of the first individual in a Phase 1 study evaluating ARQ-234, a potential biologic treatment for moderate to severe #AtopicDermatitis.
Learn more: arcutis.com/arcutis-begins-e…
#ClinicalDermatology
Jon Rees PhD retweeted
📢Passionate about making a difference?
We're looking for a dedicated and motivated CEO to lead our national charity supporting PKD patients, carers, and renal clinicians.
Join us in our mission to improve lives. Find out more and apply:pkdcharity.org.uk/about-us/v…
Jon Rees PhD retweeted
We’ve appointed 4 additional experts @oligogirl @HansbroResearch @CarolineGuiner @MilosFi37777561 to our SAB, to support developing treatments for degenerative diseases with the world's only mitochondrial platform restoring sulfide-signaling. @biotechjon
tinyurl.com/4vaamzpj
Jon Rees PhD retweeted
@BiotechJon will share insights at #BIOEuropeSpring into our first-in-class mitochondriotropic therapeutics, now validated preclinically in mammalia. These restore sulfide-signalling, which can arrest progression in degenerative conditions.
🤝 Book a mtg: lnkd.in/e2EQTn8j
Jon Rees PhD retweeted
Really interesting paper validating @MitoRxTheraLtd technology. Mitochondrial sulfide promotes life span and health span through distinct mechanisms in developing versus adult treated Caenorhabditis elegans | PNAS pnas.org/doi/abs/10.1073/pna…
Jon Rees PhD retweeted
Silicon Valley Bank UK has today been sold to @HSBC.
This transaction has been facilitated by the @bankofengland in consultation with HM Treasury.
No taxpayer money is involved and customer deposits have been protected.
Find out more ⬇️
gov.uk/government/news/gover…
Jon Rees PhD retweeted
We are finalists for ‘Best Start-up Biotech Company' at the #OBNAwards next week for our revolutionary mitochondrial-protective therapeutics!
Check out all the finalists online: obn.glueup.com/event/obn-awa…
Jon Rees PhD retweeted
Startup boasts multiple novel compounds with potential to halt progress of #age-related #disease.
@MitoRxTheraLtd’s CEO on how the biotech has several drug candidates for age-related diseases that target #mitochondrial #dysfunction.
longevity.technology/startup…
Jon Rees PhD retweeted
Lilly signs $1.25bn collaboration deal with MiNA Therapeutics - PMLiVE pmlive.com/pharma_news/lilly…
Jon Rees PhD retweeted
.@atlanticbridgev has unveiled the €80m University Bridge Fund II to back spinouts from @TrinityResInnov, @ucctechtransfer and @UCDinnovation and others in Ireland
globaluniversityventuring.co…
Jon Rees PhD retweeted
Media Coverage Alert: We made the front page! "MitoRx Therapeutics readied for launch"
mednous.com/news/mitorx-ther…
Jon Rees PhD retweeted
Evox announced Thursday a $95 million Series C to push their first rare-disease programs into the clinic in 2022.
endpts.com/evox-raises-95m-a…
Jon Rees PhD retweeted
KalVista reported topline Phase II results for its lead candidate KVD900, an oral therapy meant to stem the effects of swelling attacks caused by the rare genetic disorder hereditary angioedema.
endpts.com/kalvista-sees-a-w…
Jon Rees PhD retweeted
Press release: we intend to acquire @KymabLtd, a clinical-stage biopharma developing fully human monoclonal antibodies. sanofi.com/en/media-room/pre…
#immunooncology #immunemediated
Jon Rees PhD retweeted
We're thrilled to announce the closing of our $6.8 mil. Series A financing, co-led by @epidarex & Taiho Ventures LLC, with participation from @OSI_Updates
This enables us to progress our pipeline of cancer therapies towards clinical trials - Read more: bit.ly/35hYWQy
Jon Rees PhD retweeted
To strengthen our continued support to biotech therapeutics & AI we are also launching the o2h human health SEIS fund.
To know more, please visit: o2hventures.com/news/o2h-ven…
#o2hventures #SEIS #Investing #Biotech #Innovation
Jon Rees PhD retweeted
Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners. Seed investment from Sofinnova in 2019 formed the Swiss clinical-stage company targeting orphan neurological disorders. #biotech #neurology
sofinnovapartners.com/news/n…
ALT Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners. Seed investment from Sofinnova in 2019 formed the Swiss clinical-stage company targeting orphan neurological disorders. #biotech #neurology
Jon Rees PhD retweeted
Scoop: SR One crew completes a complicated spinout from GlaxoSmithKline. And now they have a $500M fund to invest on their own
endpts.com/scoop-sr-one-crew…
Jon Rees PhD retweeted
Fantastic news for our #portfoliocompany Oxford BioTherapeutics in expanding its #partnership with
@Boehringer to do more to target difficult-to-treat #cancers and deliver best in class treatments for #cancerpatients #backinginnovation #investinginhealthcare
#PRESS: As a fully invested research partner, we are expanding our collaboration with Oxford BioTherapeutics to advance our strong #ImmunoOncology portfolio and T-cell engager strategies. By working together, we can do more for #cancer patients ➡ bit.ly/2SPMPDM
